These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 12849233)
21. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Henchcliffe C; Schumacher HC; Burgut FT Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338 [TBL] [Abstract][Full Text] [Related]
22. Clinical trials of neuroprotection for Parkinson's disease. LeWitt PA Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583 [No Abstract] [Full Text] [Related]
23. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis. Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066 [TBL] [Abstract][Full Text] [Related]
24. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Lees AJ BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803 [TBL] [Abstract][Full Text] [Related]
26. Rasagiline in Parkinson's disease: the show must go on. Jost WH Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684 [No Abstract] [Full Text] [Related]
27. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment]. Oberpichler-Schwenk H Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119 [No Abstract] [Full Text] [Related]
28. Reexamination of the TEMPO Study. Shults CW Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778 [No Abstract] [Full Text] [Related]
29. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Fernandez HH; Chen JJ Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937 [TBL] [Abstract][Full Text] [Related]
30. [Drug therapy of Parkinson's disease]. Myllylä V Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076 [No Abstract] [Full Text] [Related]
31. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738 [No Abstract] [Full Text] [Related]
36. Drugs for Parkinson's disease. Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446 [No Abstract] [Full Text] [Related]
37. Parkinson's disease. Clarke C; Moore A Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943 [No Abstract] [Full Text] [Related]
38. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease. Müller T Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265 [TBL] [Abstract][Full Text] [Related]
39. Other pharmacological treatments for motor complications and dyskinesias. Waters C Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104 [TBL] [Abstract][Full Text] [Related]
40. [The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital]. Szász JA; Constantin V; Fazakas PA; Blényesi E; Grieb LG; Balla A; Sárig M; Szegedi K; Bartha EN; Szatmári S Orv Hetil; 2017 Dec; 158(51):2023-2028. PubMed ID: 29250969 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]